Kymera (NASDAQ: KYMR) director sells 5,500 shares after option exercise

Rhea-AI Filing Summary

Kymera Therapeutics director Pamela Esposito reported multiple transactions in the company’s common stock on January 20, 2026. She exercised stock options for 3,000 shares at $31.2 and 2,500 shares at $49.1, receiving a total of 5,500 common shares. The filing then shows sales of 400 shares at $66.68, 4,900 shares at a weighted average price of $67.9888, and 200 shares at $68.52, reducing her directly held common stock to zero shares.

The stock option grants remain outstanding after these exercises. Esposito continues to hold 10,000 options with a $31.2 exercise price expiring on June 18, 2034, and 5,000 options with a $49.1 exercise price expiring on June 15, 2031. All option shares referenced are fully vested and exercisable, and the transactions were effected under a Rule 10b5-1 trading plan dated September 17, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Esposito Pamela

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		M(1)		3,000	A	$31.2	3,000	D
Common Stock	01/20/2026		M(1)		2,500	A	$49.1	5,500	D
Common Stock	01/20/2026		S(1)		400	D	$66.68(2)	5,100	D
Common Stock	01/20/2026		S(1)		4,900	D	$67.9888(3)	200	D
Common Stock	01/20/2026		S(1)		200	D	$68.52	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$31.2	01/20/2026		M(1)			3,000	(4)	06/18/2034	Common Stock	3,000	$0	10,000	D
Stock Option (Right to Buy)	$49.1	01/20/2026		M(1)			2,500	(4)	06/15/2031	Common Stock	2,500	$0	5,000	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.40 to $66.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.47 to $68.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The shares underlying this stock option are fully vested and exercisable.

	/s/ Bruce Jacobs, as Attorney-in-Fact	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Kymera Therapeutics (KYMR) report for Pamela Esposito?

On January 20, 2026, director Pamela Esposito exercised options for 5,500 Kymera common shares and sold 5,500 shares in multiple transactions on the same date.

How many Kymera (KYMR) shares did Pamela Esposito sell and at what prices?

She sold 400 shares at $66.68, 4,900 shares at a weighted average of $67.9888, and 200 shares at $68.52, for a total of 5,500 common shares sold.

Did Pamela Esposito exercise Kymera Therapeutics stock options in this Form 4?

Yes. She exercised 3,000 options at $31.2 and 2,500 options at $49.1 for Kymera common stock, all from fully vested and exercisable stock option grants.

How many Kymera (KYMR) options does Pamela Esposito hold after these transactions?

After the reported exercises, she holds 10,000 stock options with a $31.2 exercise price expiring on June 18, 2034, and 5,000 stock options with a $49.1 exercise price expiring on June 15, 2031.

Does Pamela Esposito still own Kymera Therapeutics common stock after the reported trades?

The filing shows that after the January 20, 2026 sales, her directly held Kymera common stock position is zero shares, while she retains vested stock options.

Were the Kymera (KYMR) insider transactions made under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by Pamela Esposito.